Live Breaking News & Updates on About Actinium Pharmaceuticals

Stay updated with breaking news from About actinium pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today. ....

United States , Hannah Choe , Astellas Pharma , Avinash Desai , American Society Of Hematology Meeting Exposition , Professor Of Medicine At Ohio State University , Prnewswire Actinium Pharmaceuticals Inc , Oncology Lg Chem Life Sciences , Actimaba National Cancer Institute , Exchange Commission , Actinium Pharmaceuticals Inc , Overall Survival , Annual American Society , Hematology Meeting , Complete Remission , Assistant Professor , Ohio State University , Chief Medical Officer , Pivotal Phase , About Actinium Pharmaceuticals , National Cancer Institute , Life Sciences , Actinium Pharmaceuticals , Health Care Amp Hospitals , Pharmaceuticals , Medical Pharmaceuticals ,

Actinium Pharma (ATNM) Highlights First-In-Class HER3 Targeted Radiotherapy Data

Actinium Pharma (ATNM) Highlights First-In-Class HER3 Targeted Radiotherapy Data
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Hans Vitzthum , Development Agreement , Astellas Pharma Inc , Epicentrx Inc , Actinium Pharmaceuticals Inc , Oncology Inc , Memorial Sloan Kettering Cancer Center , American Association For Cancer Research , National Cancer Institute , Lifesci Advisors , American Association , Cancer Research , About Actinium Pharmaceuticals , Elderly Relapsed , Refractory Acute Myeloid Leukemia , Complete Remission , Event Free Survival , Acute Myeloid Leukemia , Cooperative Research , Astellas Pharma , Sci Advisors ,

Actinium Pharmaceuticals Reports 2022 Financial Results and Highlights Recent and Upcoming Clinical Data and Milestones

- Announced positive results from the pivotal Phase 3 SIERRA trial of Iomab-B in r/r AML patients ages 55+; achieved primary endpoint of dCR with high. ....

United States , Sandesh Seth , Hans Vitzthum , American Society Of Hematology , Oncology Group , Epicentrx Inc , National Institutes Of Health , Lifesci Advisors , Columbia University , Actinium Pharmaceuticals Inc , Development Agreement , Exchange Commission , Eastern Cooperative Oncology Group , National Cancer Institute , Experimental Therapeutics Clinical Trials Network , Lg Chem Company , Memorial Sloan Kettering Cancer Center , Early Access Program , Prnewswire Actinium Pharmaceuticals Inc , National Clinical Trials Network , International Blood Marrow Transplant Research , Cancer Therapy Evaluation Program , Astellas Pharma Inc , Alliance For Clinical Trials In Oncology , American College Of Radiology Imaging Network , American Association For Cancer Research ,

Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia

- Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical. ....

United States , Madhuri Vusirikala , Caroline Yarbrough , Sandesh Seth , Hans Vitzthum , Venetoclax Bcl , Sergio Giralt , Avinash Desai , Lifesci Advisors , Actinium Pharmaceuticals Inc , Division Of Hematologic Malignancies , Service At Memorial Sloan Kettering Cancer Center , Clinical Development , Complete Remission , Actinium Pharmaceuticals , Investor Conference Call , Webcast Details , Chief Medical , Chief Commercial , Deputy Head , Hematologic Malignancies , Attending Physician , Memorial Sloan Kettering Cancer Center , After Initial , Secondary Endpoints , Event Free Survival ,

Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Commercialization

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today. ....

Caroline Yarbrough , Bristol Myers Squibb , Sandesh Seth , Hans Vitzthum , Lifesci Advisors , Goizueta Business School At Emory University , Merck Co , University Of Delaware , Nijenrode University , International Business , Peter White Undergraduate Research Fellowship , Actinium Pharmaceuticals Inc , Prnewswire Actinium Pharmaceuticals Inc , Portfolio General Manager , Glaxo Smithkline , Chief Commercial , Chief Executive , Chief Business , Goizueta Business School , Emory University , Pivotal Phase , Complete Remission , About Actinium Pharmaceuticals , Elderly Relapsed , Refractory Acute Myeloid Leukemia , Sci Advisors ,